Attention-Deficit/Hyperactivity Disorder | Treatment Algorithms: Claims Data Analysis | Adult | US | 2023
Attention-deficit / hyperactivity disorder (ADHD) is one of the most common childhood mental health disorders that can continue into adulthood. This condition entails several recurring problems, including impulsivity, hyperactivity, and difficulties paying attention. Low self-esteem, unstable relationships, subpar career or academic performance, and other issues might result from ADHD in adults. Diagnosis and drug treatment among adults have historically trailed behind those of pediatric patients. However, as the prevalence of ADHD in adult patients has increased in recent years, so has industry attention towards studying adult ADHD patients in clinical trials and including these additional data in the labels for drugs earlier approved for childhood ADHD. Given the availability of multiple drugs for ADHD, it is valuable for drug marketers and developers to understand physicians’ actual prescribing behavior in adult ADHD patients. This study uses national patient-level claims data to determine the prescribing patterns of drugs for adult ADHD patients.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed adult ADHD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed adult ADHD patients?
- How has branded drugs (e.g., Vyvanse) been integrated into the treatment algorithm, and what is their source of business?
- What percentage of adult ADHD patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of adult ADHD patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated adult patients with ADHD?
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: Aytu Biopharma, Tris Pharma, Arbor Pharmaceuticals, Takeda Pharmaceuticals, Eli Lilly, Supernus Pharmaceuticals, etc.
Key drugs: Atomoxetine (Strattera, generics), Adzenys XR-ODT, Daytrana, Evekeo, guanfacine ER (Intuniv, generics), Jornay PM, methylphenidate ER (Concerta, Ritalin LA, generics), mixed amphetamine salts (Adderall XR, generics), Mydayis, Qelbree, Quillichew ER, Vyvanse, Vyvanse Chewable, etc.
SOLUTION ENHANCEMENT
The Treatment Algorithms dashboard is an interactive supplement to our PowerPoint-based claims data analysis reports and retains the full set of analyses included in the reports (i.e., newly diagnosed patients, recently treated patients, persistency, and compliance). The dashboard allows for easier navigation of data visualizations and provides more detailed analyses examining the flow of treatment regimens in newly diagnosed and recently treated patients.
